C4 Therapeutics Q2 2024 GAAP EPS $(0.26) Beats $(0.37) Estimate, Sales $12.01M Beat $4.78M Estimate, Cash, Cash Equivalents and Marketable Securities of $295.7M As Of June 30, Expected to Provide Runway into 2027
Portfolio Pulse from Benzinga Newsdesk
C4 Therapeutics reported a Q2 2024 GAAP EPS of $(0.26), beating the estimate of $(0.37). Sales were $12.01M, surpassing the $4.78M estimate. The company has $295.7M in cash, cash equivalents, and marketable securities as of June 30, expected to provide a financial runway into 2027.
August 01, 2024 | 11:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
C4 Therapeutics reported better-than-expected Q2 2024 earnings and sales, with a strong cash position expected to last until 2027.
The better-than-expected earnings and sales figures, along with a strong cash position, are likely to positively impact C4 Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100